European Psychiatry - Volume 33 - March 2016

99 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S72–S115 S95
against glutaminergic excitotoxicity in patients with OCD. Further
studies including patients with other psychiatric illnesses as con-
trols are required for confirmation of the above findings.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
Psychopharmacology and pharmacoeconomics
FC56
Impact of DRD2 polymorphisms on
prolactin level in risperidone-treated
Thai children and adolescent with
autism spectrum disorders
C. Sukasem ∗, Y. Hongkaew
Faculty of Medicine Ramathibodi hospital, Pathology, Bangkok,
Thailand
∗ Corresponding author.
Introduction A large number of studies have reported that the
prolactin concentration was significantly increased in the Taq1A
A1 allele carriers because several reports revealed that individuals
with the DRD2 Taq1A A1 allele have a reduced density of brain D2
receptors.
Objective The main aim of this study was to identify the impact
of pharmacogenetic markers associated with prolactin concentra-
tion in risperidone-treated children and adolescents with autism
spectrum disorders.
Methods One hundred and forty-seven children and adolescents
with autism, aged 3 to 19, received risperidone. The clinical data of
patients were recorded frommedical records. Prolactin levels were
measured by chemiluminescence immunoassay. Three CYP2D6 sin-
gle nucleotide polymorphisms (SNPs), CYP2D6*4 (1846G>A), *1 0
(100C>T), and *41 (2988G>A), one gene deletion (*5), and DRD2
Taq1A (rs1800497) polymorphism were genotyped by TaqMan
real-time PCR.
Results The three common allelic frequencies were CYP2D6* 10
(55.10%), *1 (32.65%) and *5 (6.12%), respectively. Patients were
grouped according to their CYP2D6 genotypes. The DRD2 geno-
type frequencies were Taq1A A2A2 (38.77%), A1A2 (41.50%), and
A1A1 (19.73%), respectively. There were statistically significant
differences in prolactin level of patients among the three groups
(P = 0.033). The median prolactin level in patients with DRD2
Taq1A A2A2 (17.80 ng/mL) was significantly higher than A1A2
(17.10 ng/mL) and A1A1 (12.70 ng/mL).
Conclusion DRD2 Taq1A A2A2 polymorphisms may be a critical
role in an influence prolactin elevation during risperidone treat-
ment in ASD.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
FC57
Detection of CYP2D6 polymorphism
using Luminex xTAG technology in
autism spectrum disorder: CYP2D6
activity score and its association with
risperidone levels
C. Sukasem ∗, S. Santon
Faculty of Medicine Ramathibodi hospital, Pathology, Bangkok,
Thailand
∗ Corresponding author.
Introduction The determination of the accurate CYP2D6 genotyp-
ing is essential in the clinical setting and individualization of drug
therapy.
Objectives In this study, was to apply the Luminex xTAG tech-
nology to detect significant CYP2D6 polymorphisms and copy
number variation, including assessment the relationship of CYP2D6
polymorphisms and risperidone plasma concentration in autism
spectrum disorder children (ASD) treated with risperidone.
Methods All 84 ASD patients included in this study had been
receiving risperidone at least for 1 month. The CYP2D6 geno-
types were determined by luminex assay. Plasma concentrations
of risperidone and 9-hydroxyrisperidone were measured using
LC/MS/MS.
Results Among the 84 patients, the most common genotype was
CYP2D6*1/*10 (26.19%). The most common allele was CYP2D6*10
(51.79%) and the second most allele was CYP2D6*1 (27.98%).
There were 46 (55.42%) classified as EM, 33 (39.76%) as IM, and
4 (4.82%) as UM. The plasma concentration of risperidone and
risperidone/9-hydroxyrisperidone ratio in the patients were sig-
nificant differences among the CYP2D6 predicted phenotype group
(P = 0.001 and P < 0.0001, respectively). Moreover, the plasma con-
centration of risperidone and risperidone/9-hydroxyrisperidone
ratio in the patients with CYP2D6 activity score 0.5 were sig-
nificantly higher than those with the CYP2D6 activity score 2.0
(P = 0.004 and P = 0.002, respectively).
Discussions The present study suggests that it would be ideal to
identify the CYP2D6 genotype of patients before prescribing and
administering risperidone. Furthermore, the use of CYP2D6 gene
scoring system to determine an individual’s metabolic capacity
may become an essential tool for a more rational and safer drug
administration.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
FC58
Angiotensin II type 1 receptor
blockade diminishes negative effect of
chronic stress on memory via
upregulation of brain-derived
neurotrophic factor
D. Wincewicz ∗, A. Juchniewicz
1 Medical University of Bialystok, Department of Clinical
Pharmacology, Bialystok, Poland
2 Medical University of Bialystok, Department of Clinical Molecular
Biology, Bialystok, Poland
∗ Corresponding author.
Introduction A critical need exists for progress in the char-
acterization of targets for pro-cognitive drug discovery. We
previously demonstrated that Telmisartan (TLM), an angiotensin
type 1 receptor (AT1) blocker and partial agonist of peroxi-
some proliferator-activated receptor gamma (PPAR ), alleviates
cognitive decline in chronically stressed rats. Understanding of
mechanistic background of this phenomenon is hampered by both
dual binding sites of TLM and limited data on the molecular conse-
quences of central AT1 blockade and PPAR activation.
Objectives To discriminate molecular effects of AT1 blockade and
PPAR activation in stress induced memory impairment.
Aims In this study, we investigated mechanism of neuroprotec-
tion provided by TLM in chronic psychological stress.
Methods We analyzed BDNF gene expression in the hippocam-
pus (HIP) and medial prefrontal cortex (mPFC) in chronically
restrained stressed Wistar rats (2.5 h, 21 days), repeatedly treated
with TLM (1mg/kg), GW9662 (0.5mg/kg) – a selective PPAR
receptor antagonist, or both in combination. TATA box binding pro-
tein (Tbp) was an internal control for expression studies.